Language

Dermatology Research

Partnering with Pace Dermatology

We have recently partnered with Pace Dermatology to bring more accessible and innovative dermatology treatments to patients in the Pacific Northwest. Patients benefit from the research expertise of the MultiCare’s Institute for Research & Innovation and the highly-skilled, passionate clinical team at Pace Dermatology. 

Dermatology studies include, but are not limited to, the following therapeutic areas:

  • Psoriasis
  • Atopic dermatitis
  • Acne
  • And other conditions

Drs. Aaron and Andrew Pace lead Pace Dermatology, with locations in Tacoma and Lakewood. They are board certified in dermatology, so patients can expect the highest level of care. 

Please click here to learn more about Pace Dermatology.

Dermatology Studies Accepting Participants

Adult 

Atopic Dermatitis 

BREEZE-AD5

Study Number: ELI LILLY I4V-MC-JAIW - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Denise Quinn, [email protected], 253.301.6990


BREEZE-AD6

Study Number: ELI LILLY I4V-MC-JAIW - A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Meagan Veitenhans, [email protected], 253-301-6990


PFIZER B7451014

Study Number: B7451014 - A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Study Info

Principal Investigator: Aaron Pace, MD 

Study Coordinator: Denise Quinn, [email protected], 253.301.6990


AD Extension Study

Study Number: Pfizer B7451015 - A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of PF04965842, with or without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD 

Study Coordinator: Denise Quinn, [email protected], 253.301.6990

Psorasis

Eli Lilly OASIS-3

Study Number I6T-MC-AMAH - A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis OASIS-3

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Denise Quinn, [email protected], 253.301.6990

Pediatrics

Atopic Dermatitis

Regeneron 1434

Study Number: R668-AD-1434 - An open-label extension study to assess the long-term safety and efficacy of Dupilumab in patients 6 months or older to <18 yers of age with atopic dermatitis.

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


Liberty AD PRESCHOOL

Study Number: R668-AD-1539 - A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab In Patients Aged ≥6 Months to <6 Years With Severe Atopic Dermatitis

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Danielle Wahinekapu, [email protected], 253-301-6992


PFIZER B7451014

Study Number: B7451014 - A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Study Info

Principal Investigator: Aaron Pace, MD

Study Coordinator: Denise Quinn, [email protected], 253.301.6990


AD Extension Study

Study Number: Pfizer B7451015 - A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of PF04965842, with or without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis

Study Info

Principal Investigator: Andrew Pace, MD

Study Coordinator: Denise Quinn, [email protected], 253.301.6990